NZ239466A - Desalted colostrum: spray dried product from retentate of - Google Patents

Desalted colostrum: spray dried product from retentate of

Info

Publication number
NZ239466A
NZ239466A NZ23946691A NZ23946691A NZ239466A NZ 239466 A NZ239466 A NZ 239466A NZ 23946691 A NZ23946691 A NZ 23946691A NZ 23946691 A NZ23946691 A NZ 23946691A NZ 239466 A NZ239466 A NZ 239466A
Authority
NZ
New Zealand
Prior art keywords
colostrum
ultra
filtration
subjecting
pasteurisation
Prior art date
Application number
NZ23946691A
Inventor
Peter Bennett Duff Whyte
Original Assignee
Us Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Agriculture filed Critical Us Agriculture
Publication of NZ239466A publication Critical patent/NZ239466A/en

Links

Description

2 3 9 4 6 6 Priority Da'.?; . ■ .ITS'.SO.
Coirvloxt Clnnr.: «Z5>oW/ Puhi^c^v'a'. T: P.O. Journ.3', . .. I3T1ST.
Patents Form No. 5 PATENTS ACT 1953 COMPLETE SPECIFICATION COLOSTRUM PREPARATION AND STORAGE '* We, MINISTER OF AGRICULTURE A BODY CORPORATE PURSUANT TO THE MINISTER OF AGRICULTURE INCORPORATION ACT 1952 of 19th Floor, Grenfell Centre, 25 Grenfell Street, Adelaide, South Australia 5000, Australia Number Date® AUG 1991, iA do hereby declare the invention for which I/we pray that a Patent may be granted to me/us, and the method by which it is to be performed, to be particularly described in and by the following statement: 23 9 4 66 This invention relates to a process for the preparation and storage of colostrum products. It is particularly applicable to preparing and storing antibody enriched colostrum without loss of the antibody activity.
Colostrum is the milk secreted by a mammal just before and for a short period after giving birth, containing antibodies to protect offspring against disease. It has been recognised in the prior art that mammals such as cows may be immunized with specific antigens. The antibody enriched colostrum may then be harvested.
A difficulty in the prior art has been that there has been no economical process for preparing and storing colostrum products.
It is known in the prior art that milk products may be spray dried to give a powdered product which may be stored. When known spray drying processes were used to process colostrum it was unexpectedly discovered that the high salt content of the colostrum was a problem which rendered known processes uneconomical.
Colostrum has an extremely high salt content. If known spray drying processes are used to process colostrum the spray drier must undergo extensive cleaning every day for approximately 10 hours to prevent corrosion of the drier. As indicated above this renders the process uneconomic and is a problem which does not relate to normal milk.
Accordingly, it is an object of the present invention to overcome or at least alleviate, one or more of the difficulties related to the prior art.
Accordingly as a first aspect of the present invention there is provided a process for the preparation of a colostrum product which process includes: providing colostrum; removing or substantially reducing the content of said colostrum; and subjecting the colostrum to a spray/' drying^^ process. ■ The inventors have found that the step of temoVal^*, XX \/ 23 9 4 66 of salt from the colostrum renders the process economic. Salt removal is significant as it reduces the likelihood of corrosion damage to stainless steel plant and reduces the necessity to wet wash drying equipment, offering a significant saving of time and money.
The colostrum may be freshly harvested colostrum or frozen colostrum. The colostrum may be bovine colostrum harvested from freshly calved cows. The colostrum may be harvested using modern milking equipment. The colostrum may be antibody enriched.
The salt may be removed by any suitable means. In a preferred embodiment the salt is removed by ultra-filtration.
Accordingly in a further aspect of the present invention, there is provided a process for the preparation of a colostrum product which process includes providing colostrum; subjecting the colostrum to an ultra-filtration process; and subjecting the filtered colostrum to a spray drying process.
The product so formed is provided in a preserved form without loss of antibody activity.
The ultra-filtration apparatus preferably removes all molecules of molecular weight less than 20,000 for example water, minerals, salts and non-protein nitrogen. Any suitable ultra-filtration apparatus may be used. In a preferred embodiment a hollow fibre ultra-filtration plant is used. The ultra-filtration step may also remove or reduce the lactose from the content of the colostrum. This is also advantageous from a medical point of view.
In a preferred aspect of the present invention the process may further include the preliminary step of pasteurisation. Low temperature, long time pasteurisation is preferably employed due to the extreme heat sensitivity of immuno-proteins. In a preferred embodiment ^he pasteurisation is conducted at approximately 63°^ approximately 30 minutes. The pasteurised colos then preferably cooled to approximately 55 239466 undergoing the ultra-filtration step. The pasteurised colostrum may suitably be cooled by regeneration.
Accordingly, a further aspect of the present invention provides a process for the preparation of a colostrum product which process includes providing colostrum; subjecting the colostrum to a pasteurisation process; subjecting the pasteurised colostrum to an ultra-filtration process; and subjecting the filtered colostrum to a spray drying process.
In a further preferred aspect of the present invention the process may further include the preliminary step of separating the colostrum. The colostrum may be preferably separated into a light phase (cream) and a heavy phase (skim). The light phase is preferably discarded.
Accordingly yet a further aspect of the present invention provides a process for the preparation of a colostrum product which process includes providing colostrum; subjecting the colostrum to a separation step and discarding the light phase; subjecting the heavy phase colostrum to a pasteurisation process; subjecting the pasteurised colostrum to an ultra-filtration process; and subjecting the filtered colostrum to a spray drying process.
Any suitable separation apparatus may be used. A suitable separation apparatus is a self desludging type apparatus.
The colostrum is preferrably pre-heated to approximately 50°C prior to the separation step. Any suitable means may be used to preheat the colostrum, for example by means of a plate heat exchanger. /s After the ultra-filtration step, it is pr< that the ultra-filtered retentate is subjected 23 9 4 6 6 evaporation step in which excess moisture is removed from the retentate. In a preferred embodiment, the excess moisture is boiled off under a vacuum of approximately -lOOkpa. At this pressure, the vapour temperature is maintained at approximately 45°C thus minimising any heat damage. Any isui table evaporator may be used. In a preferred embodiment a centritherm evaporator is used.
The concentrate may then be introduced into the spray drying chamber. The concentrate may be introduced at the same temperature at which pasteurisation has occured. In a preferred embodiment it is introduced at a temperature of 63°C. A two-fluid nozzle may be used to introduce the concentrate into the drying chamber. In a preferred embodiment, the drying chamber is maintained at approximately 170°C inlet temperature and 70°C outlet temperature. The Applicants have unexpectedly found that this drying technique which normally would be expected to inactivate the antibodies, has been found by the Applicants not to do so. Most of the energy of the spray drying is taken up as latent heat of evaporation, and accordingly there is very little particle temperature elevation. Accordingly heat damage is minimised. The dried particles preferably fall into a static fluidised bed where further drying and fines agglomeration take place. This produces a product with good dispersibility in water.
It will be understood that the steps of the process of the present invention as described above may take place in any suitable order. Other steps may also be included in the process o£ the present invention. For example in another preferred embodiment of the present application casein is removed from the milk by precipitation. This step preferably takes place after the colostrum has been subjected to a separation step and the light phase has been discarded.
The present invention will now be more fully described with reference to the accompanying drawings and^j?*Ew example. It should be understood, however, that the ^ description following is illustrative only, and should n0^.. 4 OCT 1993 m 23 94 66 be taken in any way as a restriction on the generality of the invention described above.
In the drawing: Figure 1 a flow diagram of the process according to one embodiment of the present invention. The abbreviations used are as follows, SEP=SEPARATION, PAST 1=PASTEURISATI0N, UFS-10=ULTRAFILTRATIC)N, UFS- 1 ULTRAFILTRATION , CT1B=CENTRITHERM (Thermal Evaporator), P3 HEATER=PLATE HEAT EXCHANGER, HT1=H0LDING TUBES, HT2=H0LDING TUBES and HT3=H0LDING TUBES.
EXAMPLE 1 Antibody enriched bovine colostrum was harvested from freshly calved cows using modern milking equipment. The colostrum was quickly cooled and held under refrigeration (<4°C) until it was collected. The colostrum was collected daily in a refrigerated van (0°C). Colostrum from individual farms was segregated to prevent cross-contamination.
The colostrum was weighed and tested for microbial quality, inhibitory substances and for specific antibodies to known pathogens. The colostrum was then stored at 0°C pending the results of these tests.
The liquid colostrum was pooled according to antibody content, to produce a uniform product. The pool was kept refrigerated prior to processing.
The pooled colostrum was pre-heated to 50°C by means of a plate heat exchanger and separated in a self desludging type separator. The light phase (cream) was discarded and the heavy phase (skim) was pasteurised at 63°C for 30 minutes. The pasteurised skim was cooled by regeneration to 55°C.
The skim was passed through a hollow fibre ultra-filtration plant to remove molecules of molecular weight less than 20,000; namely water, lactose, minerals, salts, non-protein nitrogen. The ultra-filtered retentate was transferred to a centritherm evaporator where excess moisture was boiled off under a vacuum of -lOOkpa. After evaporation, the concentrate underwent a further pasteurisation step at 63°C for 30 minutes to reduce microbial loading prior to spray drying.
The concentrate, at 63°C, was introduced into a j/W" N spray drying chamber of aseptic design with hepa filter#o° ijN %4 OCT 1993 239466 in the feed line, atomising air, and drying air supply, purpose built for pharmaceutical grade products. The concentrate was introduced via a two-fluid nozzle where it was atomised by heated, hepa-filtered air. The drying chamber was maintained at 220°C inlet temperature and 70°C outlet temperature. The dried particles fell into a static fluidised bed where further drying and fines agglomeration took place, producing a product with good dispersibility in water. The finished product was then packaged.
EXAMPLE 2 Antibody levels and quantities of colostrum collected from cows varies dramatically over the first week after calving. The colostrum from the first six milking was collected. For practical handling reasons all milk collected on one day was pooled at each farm with each farms milk kept separate by collection date. Each of these milk deliveries was kept separate and assessed individually for quality. Colostrum deliveries shown to be satisfactory with respect to microbial and inhibitory substances tests were pooled on the basis of quantity and haemagglutination inhibition (HAI) titre to produce a standard weight average HAI titre. This pooling step ensured that a standard product was consistently produced with respect to both the colostrum composition and antibody potency.
Approved milk pooled for processing to provide correct antibody levels was processed by skimming in a cream separator to reduce fat, low temperature pasteurisation to reduce microbiological load and-eliminate major potential pathogens, ultra filtration to concentrate protein and reduce lactose and mineral levels, including salt, evaporation under vacuum to further concentrate, and spray drying in an aseptic, pharmaceutical model spray drier with filtered air supply. Powder was packed in new food grade poly-ethylene bags within new fibre-board containers and sealed faC^tTw^5^ . * o transport. v 23 9 4 06 Production Flow Chart: TABLE 2 Separation to remove cream Milk Receival Pool raw milk Raw milk is received, weighed and stored pending quality control and release.
Approved milk is pooled according to age and potency to produce a homogeneous batch of standard potency.
Cream (milk fat) is removed by separation in a standard dairy separator.
Pasteurization 63°C for 30min Ultrafiltration Thermal evaporation under vacuum Spray dr ying Milk is heated to 63 C and held for 30 minutes in a standard pasteurisation process, to eliminate pathogens and reduce total microbial load.
Product is concentrated by reduction of water, lactose and electrolyte levels' through ultrafiltration membranes.
Product is further concentrated by low temperature evaporation under vacuum.
Product is spray dried in an aseptic spray drier. £ ft ?- ,n >;n Z-4 OCT 1993 / '23 9 4 6 Product is held in quarantine until approved for microbiological quality, moisture level and potency.
Approved bulk product packed into sachets. Packed product is returned for quality control.
Packed product is held in quarantine until approved for microbiological quality, moisture level, pack quality, potency and documentation review.
EXAMPLE 3 Table 3 lists the constituents of a sample of colostrum product which has been prepared by the process of Example 1.
TABLE 3 Colostrum Product Prepared by Process of Example 1 Moisture % Fat % Solubility Index Sc.Pts./Ext. Matter Protein (TN x 6.38)% Lactose % Ash % § 500°C Salt % Whey Protein Nitrogen mg/g Dispersability% Wettability (Sees) @ 25°C Aluminium mg/kg Penicillin Other Inhibitory Substances (As Pencillin I.U./mL) (I.U./mL) 8.2 2.4 5.0 D 73. 6 11.2 .9 0.48 >7.0 50 60+,60+,60+ 3.4 <0.0025 <0.0025 /X. 239466 The above process reduces salt content by a factor of approximately eight times. First colostrum contains approximately 32 mmol/L of NaCl. If concentrated 20 fold as in the process described the salt content of the powder would be 640 mmol/kg, which is equivalent to 3.7% of the total weight. This concentration of salt could seriously affect the stainless steel surfaces of the spray drier.
The process described reduces the salt content from 3.7% to less than 0.5% of the final powder, significantly reducing the risk of corrosion, and negating the need for frequent wet cleansing procedures as described.
Finally, it is to be understood that various other modifications and/or alterations may be made without departing from the spirit of the invention, which is defined in the following claims. r-4ocri9»a v» ZSltM

Claims (12)

WHAT WE CLAIM IS:
1. A process for the preparation of a colostrum product which process includes providing colostrum; subjecting the colostrum to an ultra-filtration process; and subjecting the filtered colostrum to a spray drying process, with proviso that the colostrum is not treated with acid to adjust pH to 5.0-6.0 and with rennin or pepsin to separate casein.
2. A process as claimed in claim 1 wherein a hollow fibre ultra-filtration apparatus is used to remove or substantially reduce the low molecular weight salt content of the colostrum.
3. A process as claimed in claim 1 or claim 2 wherein said ultra-filtration process removes substantially all molecules of molecular weight less than substantially 20,000.
4. A process as claimed in any preceding claim wherein the ultra-filtration process removes and reduces the lactose content of the colostrum. Z31 <bU 12
5. A process as claimed in any preceding claim further including subjecting the colostrum to a pasteurisation process.
6. A process as claimed in claim 5 wherein the pasteurisation process takes place prior to the ultrafiltration process.
7. A process as claimed in any preceding claim wherein the process includes a step of separating the colostrum into a light phase and a heavy phase.
8. A process as claimed in claim 7 wherein said light phase is discarded.
9. A process as claimed in claim 7 or claim 8 wherein the separation step takes place prior to the pasteurisation process.
10. A process as claimed in any preceding claim wherein the ultra-filtered colostrum is subjected to an evaporation step to remove excess moisture from the colostrum.
11. A process substantially as hereinbefore described with reference to any one of the examples or drawina. -13-
12. A colostrum product produced by the process of any preceding claim. VVE§T-WALKEFj, McCABE ,»n mwwu 'ATTORNEYS FOR THE APPLICANT I -S OCT I993gj
NZ23946691A 1990-08-17 1991-08-19 Desalted colostrum: spray dried product from retentate of NZ239466A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPK181190 1990-08-17

Publications (1)

Publication Number Publication Date
NZ239466A true NZ239466A (en) 1993-12-23

Family

ID=3774894

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ23946691A NZ239466A (en) 1990-08-17 1991-08-19 Desalted colostrum: spray dried product from retentate of

Country Status (1)

Country Link
NZ (1) NZ239466A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616927B2 (en) 1997-05-29 2003-09-09 Agresearch Limited Processes for production of immunoglobulin A in milk
WO2006037182A1 (en) 2004-10-06 2006-04-13 Agri-Biotech Pty Ltd Antibody production method
EP1889547A2 (en) 1998-04-30 2008-02-20 Numico Research Australia Pty. Ltd. A food composition and method of using same
IT202000020971A1 (en) * 2020-09-03 2022-03-03 Solime S R L PROCEDURE FOR THE PREPARATION OF CONCENTRATED COLOSTRUM

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616927B2 (en) 1997-05-29 2003-09-09 Agresearch Limited Processes for production of immunoglobulin A in milk
EP1889547A2 (en) 1998-04-30 2008-02-20 Numico Research Australia Pty. Ltd. A food composition and method of using same
WO2006037182A1 (en) 2004-10-06 2006-04-13 Agri-Biotech Pty Ltd Antibody production method
IT202000020971A1 (en) * 2020-09-03 2022-03-03 Solime S R L PROCEDURE FOR THE PREPARATION OF CONCENTRATED COLOSTRUM
WO2022049531A1 (en) * 2020-09-03 2022-03-10 Solime' S.R.L. Process for the preparation of colostrum concentrate

Similar Documents

Publication Publication Date Title
US4001198A (en) Method of recovering nutrients from cheese whey and purifying the effluent
JP5290970B2 (en) Milk heat treatment method
AU596632B2 (en) Immunologically active whey fraction and recovery process
US8603560B2 (en) Milk protein isolate and process for its preparation
US4816252A (en) Product and process for transferring passive immunity to newborn domestic animals using ultrafiltered whey containing immunoglobulins
US11672257B2 (en) Methods for making high-protein greek yogurt using membrane systems before and after fermentation
CN102124027A (en) Process for producing milk fractions rich in secretory immunoglobulins
EP0859552B1 (en) Liquid colostrum for dairy products
NZ239466A (en) Desalted colostrum: spray dried product from retentate of
AU668033B2 (en) Colostrum preparation and storage
AU644468B2 (en) Colostrum preparation
CN114403217A (en) Preparation method of low-temperature sterilized pasteurized milk
US20230255224A1 (en) Production and separation of milk fractions with electrodialysis
US4448795A (en) Process of concentrating acid whey
Tamime et al. Microstructure of concentrated and dried milk products
FI103089B (en) Colostrum whey based nutritional supplement and method for its preparation
US20210212333A1 (en) Method of Concentration of Fluid Milk using Renewable Energy
Fenelon et al. Innovations and prospects
RU2738745C1 (en) Bacteriologically pure protein product with high content of minor proteins
AU2006233196B2 (en) Enriched milk products
CN115175565A (en) Preparation of high solids and high protein lactose-free sterile milk concentrate and milk powder using forward osmosis
GB2404560A (en) Process for preparing a milk powder
AU2020266724A1 (en) Method for producing a milk or whey powder, and use of a bacteria-removing separator
KR20230154024A (en) Crystallization of Beta-Lactoglobulin Using Multiple Protein Feeds
CN112136886A (en) Milk and milk product concentration method

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
EXPY Patent expired